| |
Treatment Adherence and Virologic Response Over 48 Weeks Among Patients
Rapidly Initiating Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide
(D/C/F/TAF) in the DIAMOND Study
|
| |
| |
Reported by Jules Levin
14TH INTERNATIONAL CONFERENCE ON HIV TREATMENT AND PREVENTION ADHERENCE; JUNE 17-19, 2019; MIAMI, FLORIDA
Hélène Hardy,1,* Donghan Luo,2 Debra Israel,1 Richard Bruce Simonson,1 Keith Dunn1
1Janssen Scientific Affairs, LLC, Titusville, NJ; 2Janssen Research & Development, LLC, Titusville, NJ.
|
|
| |
| |
|
|
|
